Clinical Laserthermia Systems signs LOI with HALO Precision Diagnostics for TRANBERG Thermal Therapy System
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that their US subsidiary CLS Americas has signed a Letter of Intent (LOI) with HALO Precision Diagnostics, Inc. (HALO) for evaluation of safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System.HALO will conduct an initial post-market study treating up to twenty-five (25) patients at one or more of its HALO Ambulatory Surgery Centers in the US to evaluate the safety and short term efficacy of CLS’s TRANBERG Thermal Therapy System for treating low-to-medium risk prostate cancer